Psychedelic medicines, EU insights (PAREA)
Here's a report from PAREA ... Psychedelic Access & Research European Alliance ... commenting: "As we near the end of 2024, it's a good time to reflect on a year filled with significant developments in the field of psychedelics in Europe. The year began with the announcement of PsyPal, an EU-funded clinical trial studying psilocybin in the context of palliative care to explore whether it can help individuals cope with the psychological distress of their conditions. This marks the first time the EU has fully funded a study of a psychedelic, awarding more than €6.5 million through the EU’s Horizon Europe programme. Soon after, the EMA held a multi-stakeholder workshop on psychedelics, focusing on creating a regulatory framework for psychedelic treatments in the EU. This was an important step in aligning stakeholders and laying the groundwork for future clinical applications. Later in the year, the Dutch State Commission released its report on MDMA, concluding that MDMA-assisted therapy appears to be an effective and safe treatment for patients with chronic and treatment-resistant PTSD. The report recommended that the Dutch government facilitate the introduction and use of MDMA-assisted therapy as soon as possible. We are also delighted to share that PAREA was invited by the WHO to review the draft WHO guideline on controlled medicines, reflecting the growing global importance of our work. Finally, we are excited to announce that after several years of successful work, PAREA is starting a new chapter by becoming a legally registered organisation with a strong and multidisciplinary Board. This is a significant moment for us, and we look forward to the continued growth of our initiatives in the coming years. It has been an exciting year, and we are grateful for the ongoing support as we continue to advocate for positive change in the landscape of mental health and psychedelic therapies."
For more psychedelic news and research, visit the psychedelic health professional network homepage.